Trial of Verapamil in Chronic Rhinosinusitis

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2015
Verapamil is an L-type calcium channel blocker(CCB) which has been shown to reduce inflammation in a variety of tissues. Verapamil has also been shown to improve eosinophilic inflammation in an animal model of asthma and also functions as a P-glycoprotein(P-gp) inhibitor. A major subtype of chronic rhinosinusitis(CRS) is characterized by eosinophilic inflammation as well as P-gp overexpression. The goal of this study is to therefore see whether Verapamil may be used to treat CRS.
Epistemonikos ID: 51a45723a15ab98a586a149a36655a4b0c2e5b8c
First added on: May 12, 2024